DB05353InvestigationalSmall molecule
CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
- Mechanism
- Curator reviewed
CMC 001 is used to screen liver tumors/metastases, imaging of the biliary tract and it could be suitable for liver function studies by following the metabolism and excretion of manganese in the liver cells. Several advantages like better images, higher safety, lower costs and less inconvenience for the patient can be expected.
- Primary indication
- Investigated for use/treatment in liver cancer.Curator reviewed
- Code names
- CMC 001
What you can answer from here — as of April 23, 2025
Which companies are running trials of CMC 001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account